Cargando…
Tocilizumab for treating severe COVID‐19 pneumonia refractory to combined hydroxychloroquine, lopinavir plus ritonavir, and favipiravir: A case series
Three patients diagnosed with severe COVID‐19 pneumonia received treatment with hydroxychloroquine combined with lopinavir, ritonavir, and favipiravir. Two patients diagnosed early, received tocilizumab when the pneumonia became severe and survived. The thrid patient was diagnosed late and received...
| Autores principales: | , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7675634/ https://www.ncbi.nlm.nih.gov/pubmed/33230415 http://dx.doi.org/10.1002/ccr3.3407 |
| _version_ | 1783611680545046528 |
|---|---|
| author | Surabotsophon, Manoon Klai‐On, Yingyot Thanachartwet, Vipa Khunapornphairote, Sirote Chamnanchanunt, Supat Racharak, Theerapat Laisuan, Wannada Sahassananda, Duangjai Hapunna, Samlee Jinapuk, Somjit Leelasetakul, Suthee Desakorn, Varunee |
| author_facet | Surabotsophon, Manoon Klai‐On, Yingyot Thanachartwet, Vipa Khunapornphairote, Sirote Chamnanchanunt, Supat Racharak, Theerapat Laisuan, Wannada Sahassananda, Duangjai Hapunna, Samlee Jinapuk, Somjit Leelasetakul, Suthee Desakorn, Varunee |
| author_sort | Surabotsophon, Manoon |
| collection | PubMed |
| description | Three patients diagnosed with severe COVID‐19 pneumonia received treatment with hydroxychloroquine combined with lopinavir, ritonavir, and favipiravir. Two patients diagnosed early, received tocilizumab when the pneumonia became severe and survived. The thrid patient was diagnosed late and received tocilizumab when the disease progressed to acute respiratory distress syndrome, and died. |
| format | Online Article Text |
| id | pubmed-7675634 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2020 |
| publisher | John Wiley and Sons Inc. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-76756342020-11-19 Tocilizumab for treating severe COVID‐19 pneumonia refractory to combined hydroxychloroquine, lopinavir plus ritonavir, and favipiravir: A case series Surabotsophon, Manoon Klai‐On, Yingyot Thanachartwet, Vipa Khunapornphairote, Sirote Chamnanchanunt, Supat Racharak, Theerapat Laisuan, Wannada Sahassananda, Duangjai Hapunna, Samlee Jinapuk, Somjit Leelasetakul, Suthee Desakorn, Varunee Clin Case Rep Case Reports Three patients diagnosed with severe COVID‐19 pneumonia received treatment with hydroxychloroquine combined with lopinavir, ritonavir, and favipiravir. Two patients diagnosed early, received tocilizumab when the pneumonia became severe and survived. The thrid patient was diagnosed late and received tocilizumab when the disease progressed to acute respiratory distress syndrome, and died. John Wiley and Sons Inc. 2020-10-13 /pmc/articles/PMC7675634/ /pubmed/33230415 http://dx.doi.org/10.1002/ccr3.3407 Text en © 2020 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
| spellingShingle | Case Reports Surabotsophon, Manoon Klai‐On, Yingyot Thanachartwet, Vipa Khunapornphairote, Sirote Chamnanchanunt, Supat Racharak, Theerapat Laisuan, Wannada Sahassananda, Duangjai Hapunna, Samlee Jinapuk, Somjit Leelasetakul, Suthee Desakorn, Varunee Tocilizumab for treating severe COVID‐19 pneumonia refractory to combined hydroxychloroquine, lopinavir plus ritonavir, and favipiravir: A case series |
| title | Tocilizumab for treating severe COVID‐19 pneumonia refractory to combined hydroxychloroquine, lopinavir plus ritonavir, and favipiravir: A case series |
| title_full | Tocilizumab for treating severe COVID‐19 pneumonia refractory to combined hydroxychloroquine, lopinavir plus ritonavir, and favipiravir: A case series |
| title_fullStr | Tocilizumab for treating severe COVID‐19 pneumonia refractory to combined hydroxychloroquine, lopinavir plus ritonavir, and favipiravir: A case series |
| title_full_unstemmed | Tocilizumab for treating severe COVID‐19 pneumonia refractory to combined hydroxychloroquine, lopinavir plus ritonavir, and favipiravir: A case series |
| title_short | Tocilizumab for treating severe COVID‐19 pneumonia refractory to combined hydroxychloroquine, lopinavir plus ritonavir, and favipiravir: A case series |
| title_sort | tocilizumab for treating severe covid‐19 pneumonia refractory to combined hydroxychloroquine, lopinavir plus ritonavir, and favipiravir: a case series |
| topic | Case Reports |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7675634/ https://www.ncbi.nlm.nih.gov/pubmed/33230415 http://dx.doi.org/10.1002/ccr3.3407 |
| work_keys_str_mv | AT surabotsophonmanoon tocilizumabfortreatingseverecovid19pneumoniarefractorytocombinedhydroxychloroquinelopinavirplusritonavirandfavipiraviracaseseries AT klaionyingyot tocilizumabfortreatingseverecovid19pneumoniarefractorytocombinedhydroxychloroquinelopinavirplusritonavirandfavipiraviracaseseries AT thanachartwetvipa tocilizumabfortreatingseverecovid19pneumoniarefractorytocombinedhydroxychloroquinelopinavirplusritonavirandfavipiraviracaseseries AT khunapornphairotesirote tocilizumabfortreatingseverecovid19pneumoniarefractorytocombinedhydroxychloroquinelopinavirplusritonavirandfavipiraviracaseseries AT chamnanchanuntsupat tocilizumabfortreatingseverecovid19pneumoniarefractorytocombinedhydroxychloroquinelopinavirplusritonavirandfavipiraviracaseseries AT racharaktheerapat tocilizumabfortreatingseverecovid19pneumoniarefractorytocombinedhydroxychloroquinelopinavirplusritonavirandfavipiraviracaseseries AT laisuanwannada tocilizumabfortreatingseverecovid19pneumoniarefractorytocombinedhydroxychloroquinelopinavirplusritonavirandfavipiraviracaseseries AT sahassanandaduangjai tocilizumabfortreatingseverecovid19pneumoniarefractorytocombinedhydroxychloroquinelopinavirplusritonavirandfavipiraviracaseseries AT hapunnasamlee tocilizumabfortreatingseverecovid19pneumoniarefractorytocombinedhydroxychloroquinelopinavirplusritonavirandfavipiraviracaseseries AT jinapuksomjit tocilizumabfortreatingseverecovid19pneumoniarefractorytocombinedhydroxychloroquinelopinavirplusritonavirandfavipiraviracaseseries AT leelasetakulsuthee tocilizumabfortreatingseverecovid19pneumoniarefractorytocombinedhydroxychloroquinelopinavirplusritonavirandfavipiraviracaseseries AT desakornvarunee tocilizumabfortreatingseverecovid19pneumoniarefractorytocombinedhydroxychloroquinelopinavirplusritonavirandfavipiraviracaseseries |